Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial.

Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Antiemetics/*administration & dosage ; Gastroenteritis/*drug therapy ; Ondansetron/*administration & dosage; Administration, Oral ; Canada ; Child ; Clinical Trials, Phase III as Topic ; Cost-Benefit Analysis ; Double-Blind Method ; Emergency Medical Services ; Emergency Service, Hospital ; Humans ; Multicenter Studies as Topic ; Pragmatic Clinical Trials as Topic ; Treatment Outcome ; Vomiting/etiology

Background: There are limited treatment options that clinicians can provide to children presenting to emergency departments with vomiting secondary to acute gastroenteritis. Based on evidence of effectiveness and safety, clinicians now routinely administer ondansetron in the emergency department to promote oral rehydration therapy success. However, clinicians are also increasingly providing multiple doses of ondansetron for home use, creating unquantified cost and health system resource use implications without any evidence to support this expanding practice.
Methods/design: DOSE-AGE is a randomized, placebo-controlled, double-blinded, six-center, pragmatic clinical trial being conducted in six Canadian pediatric emergency departments (EDs). In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit. We are recruiting 1030 children (1:1 allocation via an internet-based, third-party, randomization service) to receive a 48-h supply (i.e., six doses) of ondansetron oral solution or placebo, administered on an as-needed basis. All participants, caregivers and outcome assessors will be blinded to group assignment. Outcome data will be collected by surveys administered to caregivers 24, 48 and 168 h following enrollment. The primary outcome is the development of moderate-to-severe gastroenteritis in the 7 days following the ED visit as measured by a validated clinical score (the Modified Vesikari Scale). Secondary outcomes include duration and frequency of vomiting and diarrhea, proportions of children experiencing unscheduled health care visits and intravenous rehydration, caregiver satisfaction with treatment and safety. A preplanned economic evaluation will be conducted alongside the trial.
Discussion: Definitive data are lacking to guide the clinical use of post-ED visit multidose ondansetron in children with acute gastroenteritis. Usage is increasing, despite the absence of supportive evidence. The incumbent additional costs associated with use, and potential side effects such as diarrhea and repeat visits, create an urgent need to evaluate the effect and safety of multiple doses of ondansetron in children focusing on post-emergency department visit and patient-centered outcomes.
Trial Registration: ClinicalTrials.gov: NCT03851835. Registered on 22 February 2019.

N Engl J Med. 2010 Jan 28;362(4):289-98. (PMID: 20107214)
Pediatr Emerg Care. 2020 Mar;36(3):e120-e124. (PMID: 29135900)
BMJ Open. 2019 Jun 27;9(6):e029024. (PMID: 31253625)
N Engl J Med. 2004 Sep 23;351(13):1306-13. (PMID: 15385657)
Pediatr Emerg Care. 2021 Dec 1;37(12):e1087-e1092. (PMID: 31524821)
Aliment Pharmacol Ther. 2016 Sep;44(5):438-46. (PMID: 27401959)
Evid Based Child Health. 2013 Jul;8(4):1123-37. (PMID: 23877938)
N Engl J Med. 2018 Nov 22;379(21):2002-2014. (PMID: 30462938)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
Res Synth Methods. 2011 Sep;2(3):221-2. (PMID: 26061787)
BMC Pediatr. 2015 Jul 31;15:89. (PMID: 26226953)
N Engl J Med. 2008 Jan 10;358(2):169-76. (PMID: 18184962)
JAMA. 2005 Nov 2;294(17):2203-9. (PMID: 16264162)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
Emerg Infect Dis. 2011 Jan;17(1):16-22. (PMID: 21192849)
JAMA. 2016 May 10;315(18):1966-74. (PMID: 27131100)
Clin Pediatr (Phila). 2008 May;47(4):363-71. (PMID: 18270310)
Trials. 2014 May 14;15:170. (PMID: 24885220)
Ann Emerg Med. 2002 Apr;39(4):397-403. (PMID: 11919526)
BMC Pediatr. 2012 May 31;12:58. (PMID: 22650611)
N Engl J Med. 2009 May 14;360(20):2079-89. (PMID: 19439742)
Pediatrics. 2010 Jun;125(6):e1278-85. (PMID: 20439605)
N Engl J Med. 2006 Apr 20;354(16):1698-705. (PMID: 16625009)
Pediatrics. 2002 Feb;109(2):259-61. (PMID: 11826204)
JAMA. 2010 Mar 24;303(12):1180-7. (PMID: 20332404)
Clin Microbiol Infect. 2019 Apr;25(4):454-461. (PMID: 29964235)
N Engl J Med. 2006 Jan 5;354(1):11-22. (PMID: 16394298)
N Engl J Med. 2018 Nov 22;379(21):2015-2026. (PMID: 30462939)
Pediatr Emerg Care. 2012 Apr;28(4):322-8. (PMID: 22453724)
Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. (PMID: 19758398)
Drug Saf. 1999 Feb;20(2):109-17. (PMID: 10082069)
Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2371-2379. (PMID: 31502119)
J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):514-9. (PMID: 23676445)
Paediatr Drugs. 2010 Dec 1;12(6):405-10. (PMID: 21028919)

Keywords: Child; Dehydration; Emergency service, hospital; Gastroenteritis; Ondansetron; Randomized controlled trial; Vomiting

ClinicalTrials.gov NCT03851835

0 (Antiemetics)
4AF302ESOS (Ondansetron)

Date Created: 20200529 Date Completed: 20210218 Latest Revision: 20240328

20240329

PMC7251709

10.1186/s13063-020-04347-6

32460879